Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000021454
JPRN-UMIN000021454
Completed
未知

Multi-center study for evaluating distribution of RHI in Japanese subjects without cardiovascular diseases for estimating clinical reference value of RHI in Japan - Multi-center study for evaluating distribution of RHI in Japanese subjects without cardiovascular diseases for estimating clinical reference value of RHI in Japan (RHI-J Non-CVD Study)

Jinnouchi Hospital0 sites20 target enrollmentMarch 12, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Jinnouchi Hospital
Enrollment
20
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

We could not enroll enough cases.

Registry
who.int
Start Date
March 12, 2016
End Date
December 20, 2017
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •history of cardiovascular diseases hemodialysis unstable clinical condition (severe liver disease, cancer, inflammatory disease, immune disease, severe dementia, advanced organ damage etc) absence of fingers in both hands diastolic hypotension (dBP\<40 mmHg)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Safety and efficacy of favipiravir and camostat mesilate in patients with COVID-19.COVID-19Coronavirus
JPRN-jRCTs031200436Yutaka Tokue12
Completed
Not Applicable
A Multicenter Clinical Evaluation Study to Determine the External Site Accuracy of Total Immunoglobulin E Measurement using a Novel Point-of-Care Test Device Compared to a Reference Method in Atopic Subjectsallergic asthmaatopic asthma10006436
NL-OMON44019ovartis30
Completed
Phase 2
Trial of the effectiveness of nutritional intervention for patients who are administered TS-1 after surgical resection of pancreatic cancerpancreatic cancer
JPRN-jRCT1051180068Toyama Hirochika35
Terminated
Phase 3
Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.Parkinson's DiseaseLevodopa Induced Dyskinesias (LID)
NCT02153645Adamas Pharmaceuticals, Inc.87
Completed
Not Applicable
Cohort study evaluating the efficacy of denosumab to protect against aromatase inhibitor-induced bone loss in Japanese breast cancer patients.
JPRN-UMIN000014954CYBORG (Chiba Youth Breast Oncology Research Group)500